Loading clinical trials...
Loading clinical trials...
COPD is one of the most common respiratory diseases in Greece, and maybe more than half a million Greek citizens suffer both from COPD and CVD, however their characteristics and management remain unknown. HELICOPD is a national, multicenter, prospective, non-interventional study designed to contribute to better understanding and depicting the demographic and clinical characteristics of this population, the COPD- and CVD-related adverse events in a two-years period, their quality of life and the healthcare resources use. The study is initiated and coordinated by the Hellenic Thoracic Society.
Age
35 - 99 years
Sex
ALL
Healthy Volunteers
No
Department of Respiratory Medicine, Medical School, Democritus University of Thrace, University General Hospital
Alexandroupoli, Greece
5th Pulmonary Department, "Sotiria" Chest Diseases Hospital, Athens, Greece
Athens, Greece
Start Date
October 15, 2024
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2026
Last Updated
September 10, 2025
900
ESTIMATED participants
Lead Sponsor
Hellenic Thoracic Society
NCT07477600
NCT07382258
NCT07195838
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions